linagliptin / Generic mfg. - LARVOL DELTA

Retraction Note to: Dipeptidyl peptidase-4 (DPP-4) inhibition with linagliptin reduces western diet-induced myocardial TRAF3IP2 expression, inflammation and fibrosis in female mice. (PubMed, Cardiovasc Diabetol) - No abstract available

Journal • Preclinical • Fibrosis • Immunology • Inflammation • TRAF3IP2

GLP-1 Receptor Agonists Versus DPP-4 Inhibitors and 1-Year Outcomes in Inflammatory Bowel Disease With Type 2 Diabetes or Obesity: A Propensity-Matched Analysis (ACG 2026) - " Using the TriNetX Research Network of 111 healthcare organizations, we identified adults with Crohnâs disease or ulcerative colitis and T2DM or BMI â¥30 kg/m2 receiving GLP-1RA therapy (semaglutide, liraglutide, dulaglutide, or tirzepatide) or DPP-4i therapy (sitagliptin, linagliptin, saxagliptin, or alogliptin)... After matching, 11,720 GLP-1RA users were compared with 11,720 DPP-4i users. GLP-1RA use was associated with lower hospitalization (25.0% vs 31.4%; RR 0.80, 95% CI 0.76-0.83), mortality (3.1% vs 6.0%; RR 0.52, 95% CI 0.46-0.59), systemic corticosteroid initiation (14.4% vs 16.2%; RR 0.89, 95% CI 0.81-0.98), IBD-related bowel surgery (0.6% vs 1.0%; RR 0.61, 95% CI 0.45-0.81), C. difficile infection (1.0% vs 1.4%; RR 0.69, 95% CI 0.54-0.88), bowel obstruction (1.6% vs 2.1%; RR 0.78, 95% CI 0.64-0.95), and advanced IBD therapy initiation or escalation (2.0% vs 2.6%; RR 0.77, 95% CI 0.65-0.92). Gastroparesis did not differ (0.7% vs 0.8%; RR 0.89,..."

Crohn's disease • Diabetes • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus • Ulcerative Colitis

Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. (clinicaltrials.gov) - P4 | N=92 | Completed | Sponsor: Fundacin para la Investigacin del Hospital Clnico de Valencia | N=504 ➔ 92 | Active, not recruiting ➔ Completed

Biomarker • Enrollment change • Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

GLP-1 Receptor Agonists vs DPP-4 Inhibitors and Cardiovascular Outcomes in Liver Transplant Recipients: A Propensity Score-Matched Active Comparator New-User Analysis of 3,606 Patients (ACG 2026) - "Adults with liver transplant status (Z94.4) and type 2 diabetes (E11.x) or obesity (E66.x) who were new users of GLP-1RA (semaglutide, dulaglutide, liraglutide, exenatide, tirzepatide) or DPP-4i (sitagliptin, saxagliptin, alogliptin, linagliptin) were identified using a 365-day washout for both drug classes... After matching, 1,803 pairs were identified. Post-match standardized mean differences were < 0.10 for all demographic and clinical covariates. GLP-1RA was associated with significantly lower 3-point MACE (HR 0.82, 95%CI 0.69â0.97, p=0.001)."

Clinical • Cardiovascular • Congestive Heart Failure • Diabetes • Genetic Disorders • Heart Failure • Ischemic stroke • Metabolic Disorders • Myocardial Infarction • Obesity • Pancreatitis • Transplant Rejection • Transplantation • Type 2 Diabetes Mellitus

Retraction Note: Pylorus ligation-induced hyperacidity: synergistic prophylactic effects of linagliptin and L-arginine via up-regulation of EP4 receptor subtype and improvement of vascular endothelial damage. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - No abstract available

Journal

Semaglutide and Linagliptin Enhance Antioxidant Signaling Across Multiple Peripheral Organs in a Swine Model of Cardiometabolic Disease (AHA 2026) - "Abstract is embargoed at this time."

Cardiovascular • Metabolic Disorders

Mechanism of Shengqing Jiangzhuo Granules in ameliorating chronic functional constipation with dampness obstruction and Qi stagnation pattern and associated hyperuricemia based on "gut-microbiota-barrier" axis (PubMed, Zhongguo Zhong Yao Za Zhi) - "Animals were divided into a normal group, a model group, Shengqing Jiangzhuo Granules groups with low, medium, and high doses, linagliptin group, and prucalopride succinate group. Moreover, the prescription can reverse gut microbiota dysbiosis, promote the proliferation of butyrate-producing microbiota(e.g., Faecalibacterium and Blautia), increase colonic butyrate content, activate the HIF-1α signaling pathway, and enhance the expression of tight junction proteins. In conclusion, this study gradually delves from holistic pharmacodynamics to microscopic mechanism, clarifying that the action mechanism of Shengqing Jiangzhuo Granules in exerting a multi-target and holistic improvement effect on chronic functional constipation with dampness obstruction and Qi stagnation pattern, as well as its associated hyperuricemia through regulating the "gut microbiota-butyrate-HIF-1α-intestinal barrier" axis, providing a scientific basis for its clinical popularization and..."

Journal • Constipation • Dyslipidemia • Endocrine Disorders • Gastroenterology • Gastrointestinal Disorder • Metabolic Disorders • HIF1A • OCLN • TJP1

Discovery of bioactive peptides from Arbacia lixula as dipeptidyl peptidase-IV inhibitors: An in silico approach. (PubMed, J Adv Pharm Technol Res) - "Molecular docking against DPP-IV was performed in MOE v2022.02 with linagliptin as the reference ligand; docking poses were evaluated by predicted binding energy and root mean square deviation (RMSD)...Peptides 7, 15, and 18 showed favorable in silico predicting binding, relevant DPP-IV interactions, and acceptable preliminary safety profiles as potential DPP-IV inhibitory candidates. These findings should be interpreted as computational leads that require further in vitro and in vivo validation."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Dipeptidyl peptidase-4 inhibitors suppress myofibroblastic differentiation and hyaluronan synthesis in Graves' orbitopathy fibroblasts. (PubMed, Front Endocrinol (Lausanne)) - "The effects of linagliptin and sitagliptin on fibroblast proliferation, myofibroblastic differentiation, adipogenesis, and hyaluronan production were evaluated using DAPI nuclei counts, α-smooth muscle actin (α-SMA) immunofluorescence and Western blotting, Oil Red O staining, and ELISA, respectively. These findings provide in vitro evidence that DPP4i modulate selected orbital fibroblast phenotypes related to myofibroblastic differentiation and cytokine-induced hyaluronan production. Further mechanistic, pharmacokinetic, in vivo, and clinical studies are warranted to clarify their relevance to GO-related tissue remodeling."

Journal • Diabetes • Fibrosis • Immunology • Inflammation • Metabolic Disorders • Ophthalmology • Thyroid Eye Disease • Type 2 Diabetes Mellitus • DPP4 • IL1B • TGFB1

Effects of Linagliptin on Liver Enzymes in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. (PubMed, Life (Basel)) - "No significant effects were observed for GGT, while evidence for ALP was limited to a single study and was insufficient to determine the effect of linagliptin. Overall, linagliptin demonstrated limited and inconsistent effects on liver enzyme profiles."

Journal • Retrospective data • Review • Diabetes • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Type 2 Diabetes Mellitus

Study on Improving Blood Glucose Homeostasis With Dorzagliatin Tablets in the Treatment of Type 2 Diabetes Mellitus Patients With Moderate to Severe Chronic Renal Insufficiency (clinicaltrials.gov) - P=N/A | N=206 | Not yet recruiting | Sponsor: Sun Yat-sen University

New trial • Chronic Kidney Disease • Diabetes • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

MORPHEUS-EC: A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) (clinicaltrials.gov) - P1/2 | N=219 | Terminated | Sponsor: Hoffmann-La Roche | Completed ➔ Terminated; The study was closed because the sponsor decided not to continue the development of certain treatment combinations.

Trial termination • Esophageal Adenocarcinoma • Esophageal Cancer • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • HER-2 • PD-L1 • TIGIT

Linagliptin attenuates cisplatin-induced cardiotoxicity in rats via modulation of the SIRT1/AMPK/Nrf2 signaling pathway. (PubMed, Drug Chem Toxicol) - "Linagliptin demonstrates potent cardioprotective effects against cisplatin-induced toxicity, primarily through modulation of the SIRT1/AMPK/Nrf2 signaling pathway, thereby resulting in reduced oxidative stress and inflammation. These findings suggest that linagliptin may serve as a potential adjuvant therapy to mitigate cisplatin-induced cardiotoxicity."

Journal • Preclinical • Cardiovascular • Inflammation • IL6 • TNFA • TNNI3

Comparative quantitative analysis of diabetic drug, linagliptin, by HPLC (high performance liquid chromatography) and q-NMR (quantitative nuclear magnetic resonance) techniques | Poster Board #1326 (ACS-Fall 2026) - "Future studies include validation of the q-NMR method with respect to accuracy, recovery of linagliptin from commercial samples, robustness, and stability. The advantage of q-NMR for quantitative analysis lies in its minimal solvent requirements and low waste generation, making it an environmentally friendly, green chemistry approach."

Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Short-Term Intensive Insulin Therapy as a Remission Induction Strategy in Newly Diagnosed Type 2 Diabetes Mellitus: A Systematic Review. (PubMed, Cureus) - "Another trial found that linagliptin-metformin maintenance after SIIT increased the adjusted odds of achieving HbA1c below 7.0% at 48 weeks (odds ratio 2.78, 95% confidence interval 1.37-5.65; p = 0.005), although this represented medication-supported glycemic control rather than remission...SIIT may therefore serve as a selective metabolic induction strategy in early T2DM, but durable remission remains uncertain and may depend on effective sequential treatment. Standardized remission definitions, validated response predictors, and longer comparative trials are required before routine implementation."

Journal • Review • Diabetes • Metabolic Disorders • Severe Hypoglycemia • Type 2 Diabetes Mellitus

Sex-specific cardiometabolic remodeling induced by DPP-4 inhibition under high-fat diet: insights from cardiac proteomics. (PubMed, Nutr Metab Cardiovasc Dis) - "These findings reveal a dual and context-dependent role of DPP-4 inhibition in the heart and suggest that metabolic status and sex may critically influence its cardiovascular effects. This study provides novel insights into the molecular mechanisms underlying the cardiac response to DPP-4 inhibition under conditions of metabolic stress and supports further investigation of sex-specific cardiometabolic effects."

Journal • Cardiovascular • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Dipeptidyl Peptidase-4 Inhibitors Associated Heart Failure Events in Adult Patients With Type-2 Diabetes Mellitus Treated With Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Meta-Analysis. (PubMed, Endocrinol Diabetes Metab) - "Results should be interpreted with caution because of several limitations of the study."

Clinical • Journal • Retrospective data • Review • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Pediatrics • Type 2 Diabetes Mellitus

Linagliptin Improves Bone Strength and Reduces Adiposity without Affecting Bone Architecture in C57BL/6J Wild Type Mice (ASBMR 2026) - No abstract available

Preclinical • Obesity

Efficacy of SGLT2 versus DPP4 in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Multicenter Propensity-Matched Real-World Study (BSG 2026) - "Patients newly initiating SGLT2is (n=111,357; e.g., empagliflozin, dapagliflozin, canagliflozin) or DPP4is (n=43,868; e.g., sitagliptin, linagliptin) without cross-exposure were identified. While hospitalization benefits were short-term and MACE rates were modestly higher with SGLT2is, these findings support preferential consideration of SGLT2is in MASLD patients requiring antidiabetic therapy. Download figure Open in new tab Download powerpoint Abstract FP25 Figure 1"

Clinical • Real-world • Real-world evidence • Cardiovascular • CNS Disorders • Diabetes • Dyslipidemia • Genetic Disorders • Hepatic Encephalopathy • Hepatology • Hypertension • Liver Failure • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • Type 2 Diabetes Mellitus

Comparison of the permeability of DPP-4 inhibitors-sitagliptin, vildagliptin, linagliptin, and alogliptin-in placental barrier cell models and exploration of their transport mechanisms by LC-MS/MS. (PubMed, BMC Pregnancy Childbirth) - "Vildagliptin had the lowest accumulation and permeability in placental cells among the four DPP-4 inhibitors. There might be carrier-mediated transmembrane transport of linagliptin, alogliptin, sitagliptin and vildagliptin, but ENTs, CNTs and OAT4 were not involved in. This study provides a basis for future research on their safety during pregnancy."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov) - P1/2 | N=314 | Terminated | Sponsor: Hoffmann-La Roche | Completed ➔ Terminated; Study was closed early as the sponsor decided not to continue development of certain treatment combinations.

Trial termination • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

Protective Role of Linagliptin in Cisplatin-Mediated Liver Injury: Involvement of STAT3 and AMPK/SIRT1/PGC-1alpha Mitochondrial Energy Sensing Networks. (PubMed, Adv Pharmacol Pharm Sci) - "The results indicate that Lina protects against Cis-induced liver damage by leveraging its antioxidant, anti-inflammatory, and metabolic regulation properties. This study offers new insights into potential strategies for mitigating Cis-induced hepatotoxicity and enhancing its therapeutic index in cancer treatment."

Journal • Hepatology • Liver Failure • Oncology • AMPK • PPARGC1A • SIRT1 • STAT3 • TGFB1

Green HPLC-PDA method for simultaneous determination of linagliptin and cefixime with pharmacokinetic application in rats. (PubMed, Sci Rep) - "The results demonstrated that co-administration of LIN and CEF significantly altered their bioavailability: LIN Cmax increased by 63.2% and AUC increased by 134.2%, while CEF Cmax decreased by 27.3% and AUC decreased by 23.3%, indicating a bidirectional pharmacokinetic interaction, and underscoring the need for careful monitoring during combination therapy.The greenness of the proposed HPLC-PDA method was evaluated using four metric tools and the findings confirmed the method's minimal environmental impact. In conclusion, the developed HPLC-PDA method not only provides a reliable tool for therapeutic drug monitoring in clinical practice but also establishes a robust framework for future investigations into drug-drug interactions in human therapeutics."

Journal • PK/PD data • Preclinical • Diabetes • Infectious Disease • Metabolic Disorders • Type 2 Diabetes Mellitus

Incretin-based therapies and altered myocardial metabolism in a swine model of ischemic heart disease in the setting of metabolic syndrome. (PubMed, Surgery) - "Glucagon-like peptide-1 receptor agonist semaglutide and dipeptidyl peptidase-4 inhibitor linagliptin are associated with reduced fatty acid oxidation and increased glucose metabolism in a swine model of coronary artery disease with metabolic syndrome."

Journal • Cardiovascular • Coronary Artery Disease • Heart Failure • Metabolic Disorders

GLP1-AD-TTE: GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation (clinicaltrials.gov) - P=N/A | N=213891 | Completed | Sponsor: West China Hospital

New trial • Real-world evidence • Alzheimer's Disease • CNS Disorders • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus